KNCV/Challenge TB, Kano Regional Office, Kano, Nigeria.
Department of Medicine, Bayero University, Kano, Nigeria.
PLoS One. 2019 Nov 19;14(11):e0225165. doi: 10.1371/journal.pone.0225165. eCollection 2019.
Drug-Resistant tuberculosis (DR-TB) is estimated to cause about 10% of all TB related deaths. There is dearth of data on determinants of DR-TB mortality in Nigeria. Death among DR-TB treated cohorts in Nigeria from 2010 to 2013 was 30%, 29%, 15% and 13% respectively. Our objective was to identify factors affecting survival among DR-TB patients in northern Nigeria.
Demographic and clinical data of all DR-TB patients enrolled in Kano, Katsina and Bauchi states of Nigeria between 1st February 2015 and 30th November 2016 was used. Survival analysis was done using Kaplan-Meier and multiple regression with Cox proportional hazard modeling.
Mean time to death during treatment is 19.2 weeks and 3.9 weeks among those awaiting treatment. Death was recorded among 38 of the 147 DR-TB patients assessed. HIV co-infection significantly increased probability of mortality, with an adjusted hazard ratio (aHR) of 2.35, 95% CI: 1.05-5.29, p = 0.038. Treatment delay showed significant negative association with survival (p = 0.000), not starting treatment significantly reduced probability of survival with an aHR of 7.98, 95% CI: 2.83-22.51, p = 0.000. Adjusted hazard ratios for patients started on treatment more than eight weeks after detection or within two to four weeks after detection, was beneficial though not statistically significant with respective p-values of 0.056 and 0.092. The model of care (facility vs. community-based) did not significantly influence survival.
Both HIV co-infected DR-TB patients and DR-TB patients that fail to start treatment immediately after diagnosis are at significant risk of mortality. Our study showed no significant difference in mortality based on models of care. The study highlights the need to address programmatic and operational issues pertaining to treatment delays and strengthening DR-TB/HIV co-management as key strategies to reduce mortality.
耐多药结核病(DR-TB)据估计占所有结核病相关死亡的 10%左右。尼日利亚缺乏关于 DR-TB 死亡率决定因素的数据。2010 年至 2013 年,尼日利亚接受 DR-TB 治疗的队列中,分别有 30%、29%、15%和 13%的患者死亡。我们的目的是确定影响尼日利亚北部 DR-TB 患者生存的因素。
使用 2015 年 2 月 1 日至 2016 年 11 月 30 日在尼日利亚卡诺、卡齐纳和包奇州登记的所有 DR-TB 患者的人口统计学和临床数据。使用 Kaplan-Meier 和 Cox 比例风险模型进行多变量回归进行生存分析。
治疗期间的平均死亡时间为 19.2 周,等待治疗的患者为 3.9 周。在评估的 147 例 DR-TB 患者中,有 38 例死亡。HIV 合并感染显著增加了死亡率的可能性,调整后的危险比(aHR)为 2.35,95%可信区间:1.05-5.29,p=0.038。治疗延迟与生存呈显著负相关(p=0.000),未开始治疗显著降低了生存的可能性,aHR 为 7.98,95%可信区间:2.83-22.51,p=0.000。检测后 8 周以上或检测后 2-4 周开始治疗的患者的调整后的危险比虽然没有统计学意义,但分别为 0.056 和 0.092。治疗模式(医疗机构与社区为基础)对生存没有显著影响。
HIV 合并感染的 DR-TB 患者和诊断后未能立即开始治疗的 DR-TB 患者均面临显著的死亡风险。我们的研究表明,基于治疗模式,死亡率没有显著差异。该研究强调需要解决与治疗延迟相关的方案和运营问题,并加强 DR-TB/HIV 联合管理,作为降低死亡率的关键策略。